NCT00453323Unknown2 期
A Phase II Study of Weekly Paclitaxel and Capecitabine in Patients With Metastatic or Recurrent Esophageal Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 入组人数
- 33
- 试验地点
- 1
- 主要终点
- To evaluate the response rate
研究概览
简要总结
Capecitabine is an orally administered fluoropyrimidine that is converted by 5-FU by thymidine phosphorylase (TP), preferentially in tumor tissues and has demonstrated activity as single agent in patients with gastrointestinal cancer. Up-regulation of TP after taxane treatment in vitro suggested that there may be synergistic effects in combined treatment with taxane and capecitabine. The combination of taxane and capecitabine was reported to be highly active against non-small cell lung cancer, breast cancer, and stomach cancer.
详细描述
Paclitaxel-80 mg/m2/IV D1 & D8 q 3 weeks Capecitabine-900 mg/m2/PO twice daily Days 1-14 q 3 weeks
Patients receive treatment every 3 weeks till disease progression.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed esophageal cancer with histology of squamous carcinoma or adenocarcinoma
- •Clinically diagnosed metastatic or recurrent esophageal cancer according to Sixth Edition of the AJCC Cancer Staging Manual (Appendix V)
- •At least 18 years old
- •Disease status must be that of measurable disease defined as RECIST:Lesions that can be accurately measured in at least one dimension > 10 mm with chest x-ray, spiral CT scan or physical examination
- •ECOG performance status 0-2
- •No prior radiotherapy to measurable lesion(s) but previous surgery and/or chest radiotherapy for the primary lesion is allowed
- •Adequate major organ function including the following:Hematologic function: WBC ≥ 3,500/mm3 or absolute neutrophil count (ANC) ≥ 1,500/mm3, platelet count ≥ 100,000/mm3Hepatic function: bilirubin ≤ 1.5 x UNL , AST/ALT levels ≤ 2.5 x UNLRenal function: serum creatinine ≤ 1.5mg/dL
- •Patients should sign an informed consent
- •If female: childbearing potential either terminated by surgery, radiation, or menopause, or attenuated by use of an approved contraceptive method (intrauterine device [IUD], birth control pills, or barrier device) during and for 3 months after trial. If male, use of an approved contraceptive method during the study and 3 months afterwards. Females with childbearing potential must have a urine negative hCG test within 7 days prior to the study enrollment.
排除标准
- •MI within preceding 6 months or symptomatic heart disease including unstable angina, congestive heart failure, or uncontrolled arrhythmia
- •Serious concurrent infection or nonmalignant illness that is uncontrolled or whose control may be jeopardized by complication of study therapy
- •Pregnant or nursing women
- •Other malignancy with the past 5 years except adequately treated cutaneous basal cell carcinoma or uterine cervix in situ cancer
- •Psychiatric disorder that would preclude compliance.
- •Major surgery other than biopsy within the past two weeks
研究组 & 干预措施
study arm
Experimental
干预措施: Paclitaxel (Drug)
study arm
Experimental
干预措施: Capecitabine (Drug)
结局指标
主要结局
To evaluate the response rate
时间窗: the ratio between the number of responders and number of patients assessable for tumor response
次要结局
- To access the toxicity(the first day of the treatment to 30 days after the last dose of study drug)
- To estimate the time to progression and overall survival(the first day of treatment to the date that disease progression is reported)
- To evaluate the expression of TP in tumor tissues as a predictive marker for paclitaxel-capecitabine chemotherapy.(before the first treatment)
- To estimate the overall survival(the first day of the treatment to death date)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast CancerMetastatic Breast CancerNCT00216021Hoosier Cancer Research Network25
已完成
不适用
A Phase II Study of Paclitaxel+Cisplatin+5-Fluorouracil in Unresectable Advanced or Recurrent Gastric Cancernresectable Advanced or Recurrent Gastric CancerJPRN-UMIN000002988on profit foundation: Epidemiological and Clinical Research Information Network40
终止
2 期
CHFR Methylation Status Esophageal Cancer StudyEsophageal CancerNCT01372202Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins31
终止
2 期
Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast CancerMetastatic Breast CancerNCT00216073Hoosier Cancer Research Network11
已完成
4 期
Pharmacology-driven Dosing of Fluoropyrimidines in Cancer PatientsColorectal CancerNCT01641458Cantonal Hospital of St. Gallen37